AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2025
Jul 3, 2025
32159_dirs_2025-07-03_776ed2a2-fbf4-4bd1-a4de-41bd29caf558.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-07-01
Reporting Person: Karas Eric (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-07-01 | Common Stock | M | 15000 | $1.5 | Acquired | 25315 | Direct |
| 2025-07-01 | Common Stock | S | 15000 | $16.9907 | Disposed | 10315 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-07-01 | Stock Option (Right to Buy) | $1.50 | M | 15000 | Disposed | 2032-05-23 | Common Stock (15000) | Direct |
Footnotes
F1: Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
F3: The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4: Immediately exercisable.